Total Payments
$3,442
2021 Payments
$2,435
Companies
14
Transactions
39
Medicare Patients
523
Medicare Billing
$90,974
Payment Breakdown by Category
Consulting$2,398 (69.6%)
Food & Beverage$874.63 (25.4%)
Education$170.10 (4.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $2,398 | 1 | 69.6% |
| Food and Beverage | $874.63 | 28 | 25.4% |
| Education | $170.10 | 10 | 4.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $2,520 | 2 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $278.43 | 14 | $0 (2021) |
| Janssen Biotech, Inc. | $155.34 | 4 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $107.90 | 2 | $0 (2019) |
| Genentech USA, Inc. | $106.65 | 1 | $0 (2018) |
| PFIZER INC. | $94.38 | 7 | $0 (2021) |
| Janssen Scientific Affairs, LLC | $54.31 | 1 | $0 (2019) |
| MEDIVATION FIELD SOLUTIONS LLC | $29.54 | 2 | $0 (2018) |
| Lilly USA, LLC | $21.66 | 1 | $0 (2017) |
| Astellas Pharma US Inc | $18.15 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $2,435 | 4 | AstraZeneca Pharmaceuticals LP ($2,398) |
| 2020 | $103.82 | 5 | E.R. Squibb & Sons, L.L.C. ($52.20) |
| 2019 | $419.81 | 12 | Janssen Biotech, Inc. ($155.34) |
| 2018 | $462.21 | 17 | E.R. Squibb & Sons, L.L.C. ($194.95) |
| 2017 | $21.66 | 1 | Lilly USA, LLC ($21.66) |
All Payment Transactions
39 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/15/2021 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $2,397.50 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 03/11/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $11.97 | General |
| Category: Oncology | ||||||
| 01/13/2021 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $13.34 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2020 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $13.34 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2020 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $13.34 | General |
| Category: ONCOLOGY | ||||||
| 08/19/2020 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $13.34 | General |
| Category: ONCOLOGY | ||||||
| 07/13/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $52.20 | General |
| Category: Oncology | ||||||
| 02/18/2020 | Janssen Pharmaceuticals, Inc | ERLEADA (Drug) | Education | In-kind items and services | $11.60 | General |
| Category: Oncology | ||||||
| 10/03/2019 | Janssen Biotech, Inc. | Erleada (Drug), DARZALEX | Food and Beverage | In-kind items and services | $20.96 | General |
| Category: Oncology | ||||||
| 08/05/2019 | PFIZER INC. | VIZIMPRO (Drug) | Education | In-kind items and services | $15.32 | General |
| Category: ONCOLOGY | ||||||
| 08/05/2019 | PFIZER INC. | BAVENCIO (Drug) | Education | In-kind items and services | $14.65 | General |
| Category: ONCOLOGY | ||||||
| 08/05/2019 | PFIZER INC. | LORBRENA (Drug) | Education | In-kind items and services | $11.05 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $117.93 | General |
| Category: Oncology | ||||||
| 06/18/2019 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: Oncology | ||||||
| 05/30/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $8.15 | General |
| Category: Oncology | ||||||
| 05/01/2019 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Food and Beverage | Cash or cash equivalent | $19.31 | General |
| Category: Oncology | ||||||
| 02/21/2019 | Novartis Pharmaceuticals Corporation | AFINITOR (Drug), KISQALI | Food and Beverage | In-kind items and services | $12.06 | General |
| Category: ONCOLOGY | ||||||
| 02/12/2019 | Janssen Biotech, Inc. | DARZALEX (Biological), Erleada | Food and Beverage | In-kind items and services | $8.30 | General |
| Category: Oncology | ||||||
| 02/04/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $122.18 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/22/2019 | Janssen Scientific Affairs, LLC | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $54.31 | General |
| Category: Oncology | ||||||
| 12/19/2018 | Astellas Pharma US Inc | XOSPATA (Drug), XTANDI | Food and Beverage | In-kind items and services | $18.15 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $12.42 | General |
| Category: Oncology | ||||||
| 11/08/2018 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $1.16 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 3 | 109 | 121 | $38,021 | $10,093 |
| 2020 | 5 | 414 | 837 | $254,317 | $80,881 |
Total Patients
523
Total Services
958
Medicare Billing
$90,974
Procedure Codes
8
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 62 | 66 | $19,272 | $5,210 | 27.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 36 | 41 | $15,949 | $4,167 | 26.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 11 | 14 | $2,800 | $716.67 | 25.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 183 | 450 | $131,400 | $38,778 | 29.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 127 | 228 | $88,692 | $27,146 | 30.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 39 | 39 | $20,613 | $6,797 | 33.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 38 | 87 | $7,600 | $5,192 | 68.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 27 | 33 | $6,012 | $2,969 | 49.4% |
About Dr. Neil Barth, M.D
Dr. Neil Barth, M.D is a Hematology & Oncology healthcare provider based in Newport Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/06/2007. The National Provider Identifier (NPI) number assigned to this provider is 1245379858.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Neil Barth, M.D has received a total of $3,442 in payments from pharmaceutical and medical device companies, with $2,435 received in 2021. These payments were reported across 39 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($2,398).
As a Medicare-enrolled provider, Barth has provided services to 523 Medicare beneficiaries, totaling 958 services with total Medicare billing of $90,974. Data is available for 2 years (2020–2021), covering 8 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Newport Beach, CA
- Active Since 02/06/2007
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1245379858
Products in Payments
- LYNPARZA (Drug) $2,398
- OPDIVO (Biological) $237.99
- IMBRUVICA (Drug) $180.39
- IMFINZI (Drug) $122.18
- TECENTRIQ (Biological) $106.65
- KISQALI (Drug) $95.84
- INLYTA (Drug) $53.36
- CYRAMZA (Drug) $21.66
- Erleada (Drug) $20.96
- SPRYCEL (Drug) $19.97
- EMPLICITI (Biological) $19.31
- XOSPATA (Drug) $18.15
- KEYTRUDA (Biological) $17.08
- Imbruvica (Drug) $15.59
- VIZIMPRO (Drug) $15.32
- IBRANCE (Drug) $15.20
- BAVENCIO (Drug) $14.65
- XTANDI (Drug) $14.34
- AFINITOR (Drug) $12.06
- ERLEADA (Drug) $11.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Newport Beach
Misagh Karimi, Md, MD
Hematology & Oncology — Payments: $951,032
Hematology & Oncology $951,032
Dr. Andrea Stebel, M.d, M.D
Hematology & Oncology — Payments: $515,023
Hematology & Oncology $515,023
Dr. George Semeniuk, M.d, M.D
Hematology & Oncology — Payments: $364,855
Hematology & Oncology $364,855
Robert Dillman, Md Facp, MD FACP
Hematology & Oncology — Payments: $49,107
Hematology & Oncology $49,107
Dr. Simon Khagi, M.d, M.D
Hematology & Oncology — Payments: $43,769
Hematology & Oncology $43,769
Dr. David Benjamin, Md, MD
Hematology & Oncology — Payments: $32,796
Hematology & Oncology $32,796